{"id":745683,"date":"2018-08-03T05:30:00","date_gmt":"2018-08-03T05:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/"},"modified":"2025-11-07T01:27:08","modified_gmt":"2025-11-07T06:27:08","slug":"selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/","title":{"rendered":"Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1"},"content":{"rendered":"<p>\n      AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S. and<br \/>\n      Canada, today announced that the European Medicines Agency (EMA) has<br \/>\n      granted orphan designation to selumetinib, a MEK 1\/2 inhibitor, for the<br \/>\n      treatment of neurofibromatosis type 1 (NF1).\n    <\/p>\n<p>\n      NF1 is an incurable genetic condition that affects one in 3,000 newborns<br \/>\n      worldwide. The severity of signs and symptoms associated with NF1 can be<br \/>\n      highly variable, are often mild-to-moderate and may include skin, nerve<br \/>\n      and skeletal manifestations.<sup> <\/sup>Plexiform neurofibromas (PNs)<br \/>\n      are benign tumors on nerve sheaths that develop in 20-50 percent of<br \/>\n      patients and, as they continue to increase in number and size, cause<br \/>\n      moderate-to-severe morbidities such as pain, motor dysfunction and<br \/>\n      disfigurement.\n    <\/p>\n<p>\n      Sean Bohen, executive vice president, global medicines development and<br \/>\n      chief medical officer, at AstraZeneca, said, \u201cThere is no cure for NF1,<br \/>\n      a life-long and devastating condition, and current treatment choices for<br \/>\n      these patients are very limited. The granting of an orphan designation<br \/>\n      is a positive step forward for children with NF1 and their families.\u201d\n    <\/p>\n<p>\n      Dr. Roy Baynes, senior vice president and head of global clinical<br \/>\n      development, chief medical officer, Merck Research Laboratories, said,<br \/>\n      \u201cNF1 is a relatively rare disease, but can lead to life-threatening<br \/>\n      complications in those affected by it. This underscores the importance<br \/>\n      of this collaborative effort between Merck and our partner, AstraZeneca,<br \/>\n      to help patients impacted by this debilitating genetic condition.\u201d\n    <\/p>\n<p>\n      The potential benefit of selumetinib in NF1 is being explored in the<br \/>\n      Phase 1\/2 SPRINT trial in pediatric patients with inoperable NF1-related<br \/>\n      PNs. Select findings were presented recently at the 2018 American<br \/>\n      Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by the<br \/>\n      principal investigators at the National Cancer Institute (NCI). Full<br \/>\n      results are expected later in 2018.\n    <\/p>\n<p>\n      Orphan designation is a status assigned to a medicine intended for use<br \/>\n      in rare diseases. To be granted orphan status by the EMA, a medicine<br \/>\n      must be intended for the treatment, prevention or diagnosis of a disease<br \/>\n      that is seriously debilitating\/life threatening and has a prevalence of<br \/>\n      up to five in 10,000 in the European Union (EU). Additionally, the<br \/>\n      intended medicine must aim to provide significant benefit to those<br \/>\n      affected by the condition. Orphan designation is conferred following a<br \/>\n      positive opinion by the EMA&#8217;s Committee for Orphan Medicinal Products.<br \/>\n      Selumetinib was granted Orphan Drug Designation (ODD) by the U.S. Food<br \/>\n      and Drug Administration (FDA) for the treatment of NF1 in February 2018.\n    <\/p>\n<p>\n      <b>About Selumetinib<\/b>\n    <\/p>\n<p>\n      Selumetinib is an MEK 1\/2 inhibitor and potential new medicine licensed<br \/>\n      by AstraZeneca from Array BioPharma Inc. in 2003. AstraZeneca and Merck<br \/>\n      entered a co-development and co-commercialization agreement for<br \/>\n      selumetinib in 2017.\n    <\/p>\n<p>\n      The NF1 gene provides instructions for making a protein called<br \/>\n      neurofibromin, which negatively regulates the RAS\/MAPK pathway, helping<br \/>\n      to control cell growth, differentiation and survival. Mutations in the<br \/>\n      NF1 gene may result in dysregulations in RAS\/RAF\/MEK\/ERK signaling,<br \/>\n      which can cause cells to grow, divide and copy themselves in an<br \/>\n      uncontrolled manner, and may result in tumor growth. Selumetinib<br \/>\n      inhibits the MEK enzyme in this pathway, potentially leading to<br \/>\n      inhibition of tumor growth. It is also being explored as a monotherapy<br \/>\n      and in combination with other treatments in other ongoing trials.\n    <\/p>\n<p>\n      <b>About neurofibromatosis type 1 (NF1)<\/b>\n    <\/p>\n<p>\n      NF1 is caused by a spontaneous or inherited mutation in the NF1 gene and<br \/>\n      affects approximately one in 3,000 births. The disease is associated<br \/>\n      with many symptoms, including soft lumps on and under the skin<br \/>\n      (subcutaneous neurofibromas), skin pigmentation (cafe au lait spots)<br \/>\n      and, in 20-50 percent of patients, benign tumors on the nerve sheaths<br \/>\n      (plexiform neurofibromas). These plexiform neurofibromas can cause<br \/>\n      morbidities such as pain, motor dysfunction and disfigurement.\n    <\/p>\n<p>\n      People with NF1 may experience a number of other complications such as<br \/>\n      learning difficulties, visual impairment, twisting and curvature of the<br \/>\n      spine, high blood pressure and epilepsy. NF1 also increases a person\u2019s<br \/>\n      risk of developing other cancers, including malignant brain and<br \/>\n      peripheral nerve sheath tumors and leukemia. Symptoms begin during early<br \/>\n      childhood, with varying degrees of severity, and can reduce life<br \/>\n      expectancy by up to 15 years.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada, announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA<sup>\u00ae<\/sup> (olaparib), the<br \/>\n      world\u2019s first PARP inhibitor and potential new medicine selumetinib, a<br \/>\n      MEK inhibitor, for multiple cancer types. Working together, the<br \/>\n      companies will develop LYNPARZA<i> <\/i>and selumetinib in combination<br \/>\n      with other potential new medicines and as monotherapies. Independently,<br \/>\n      the companies will develop LYNPARZA and selumetinib in combination with<br \/>\n      their respective PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51841414&amp;newsitemid=20180803005038&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=b5d42d9c16e14dc0ece6b30fab6c1709\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51841414&amp;newsitemid=20180803005038&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=9ae61dff86dee153e28e4edce9062e64\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51841414&amp;newsitemid=20180803005038&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=9d86ee124439e8bbf986fc1233b02dd2\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51841414&amp;newsitemid=20180803005038&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=569f2a8b38e2639c7087fdb36a615d93\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51841414&amp;newsitemid=20180803005038&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=0e331b488ffd184206b7172288fce798\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51841414&amp;newsitemid=20180803005038&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=c1670dda1ffc0c1d3888fb04b7675dd7\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51841414&amp;newsitemid=20180803005038&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=0a8875f04749d01872594d59cd9a6424\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51841414&amp;newsitemid=20180803005038&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=ff688dbd4b89784a800181c24c138dc2\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180803005038r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       For Merck &amp; Co., Inc.<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Michael        Close, 267-305-1211<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, today announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1\/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). NF1 is an incurable genetic condition that affects one in 3,000 newborns worldwide. The severity of signs and symptoms associated with NF1 can be highly variable, are often mild-to-moderate and may include skin, nerve and skeletal manifestations. Plexiform neurofibromas (PNs) are benign tumors on nerve sheaths that develop in 20-50 percent of patients and, as they continue to increase in number and size, cause moderate-to-severe morbidities such as pain, motor dysfunction and disfigurement. Sean Bohen, executive vice president, global medicines development and chief medical officer, at AstraZeneca, said, \u201cThere is no cure for NF1, a life-long and devastating condition, and current treatment choices for these patients are very limited.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289],"class_list":["post-745683","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, today announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1\/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). NF1 is an incurable genetic condition that affects one in 3,000 newborns worldwide. The severity of signs and symptoms associated with NF1 can be highly variable, are often mild-to-moderate and may include skin, nerve and skeletal manifestations. Plexiform neurofibromas (PNs) are benign tumors on nerve sheaths that develop in 20-50 percent of patients and, as they continue to increase in number and size, cause moderate-to-severe morbidities such as pain, motor dysfunction and disfigurement. Sean Bohen, executive vice president, global medicines development and chief medical officer, at AstraZeneca, said, \u201cThere is no cure for NF1, a life-long and devastating condition, and current treatment choices for these patients are very limited.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\\\/\",\"name\":\"Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-08-03T05:30:00+00:00\",\"dateModified\":\"2025-11-07T06:27:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/","og_locale":"en_US","og_type":"article","og_title":"Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1 - Merck.com","og_description":"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, today announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1\/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). NF1 is an incurable genetic condition that affects one in 3,000 newborns worldwide. The severity of signs and symptoms associated with NF1 can be highly variable, are often mild-to-moderate and may include skin, nerve and skeletal manifestations. Plexiform neurofibromas (PNs) are benign tumors on nerve sheaths that develop in 20-50 percent of patients and, as they continue to increase in number and size, cause moderate-to-severe morbidities such as pain, motor dysfunction and disfigurement. Sean Bohen, executive vice president, global medicines development and chief medical officer, at AstraZeneca, said, \u201cThere is no cure for NF1, a life-long and devastating condition, and current treatment choices for these patients are very limited.","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:08+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/","name":"Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-08-03T05:30:00+00:00","dateModified":"2025-11-07T06:27:08+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"e1eff9c4-d96a-4e68-b651-68b695b8cd8b","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745683\/revisions"}],"predecessor-version":[{"id":3675028,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745683\/revisions\/3675028"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745683"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}